Key Takeaways
- • Even Healthcare is raising INR 208.24 crore ($22 million) in a Series B funding round led by Khosla Ventures, which will contribute INR 145 crore, with participation from DLB Ventures (INR 38.88 crore), Simon Fiduciaria (INR 22.67 crore), ADBEEV LLP, and Better Capital.
- • The round values Even Healthcare at approximately $300 million post-money, representing significant growth for the 2020-founded health tech startup following its $20 million Series A raise in January 2026.
- • Even operates a membership-based healthcare model integrating primary care, diagnostics, and hospital services, with care teams maintaining patient relationships across consultations, hospitalization, and post-discharge recovery rather than transactional engagement.
- • The company demonstrated strong revenue momentum in FY25 with INR 25.43 crore in revenue—a more than fourfold increase year-over-year—though operating losses widened to INR 90.15 crore as the company scales its care delivery model.
- • This is Even Healthcare's second significant funding event in 2026, signaling continued institutional confidence in the membership-based healthcare model as a scaled alternative to traditional transactional healthcare delivery in India.
Summary
Even Healthcare, a Bengaluru-based health tech startup, is closing a Series B funding round at INR 208.24 crore (approximately $22 million), according to regulatory filings cited by industry sources. Khosla Ventures is leading the round with a commitment of INR 145 crore, supplemented by contributions from DLB Ventures (INR 38.88 crore), Simon Fiduciaria (INR 22.67 crore), ADBEEV LLP, and Better Capital. The funding round values the company at approximately $300 million on a post-money basis, reflecting investor confidence in Even's scalable healthcare model.
Founded in 2020, Even Healthcare differentiates itself through a membership-based care model that departs from traditional transactional healthcare engagement. The company provides integrated primary care, diagnostics, and hospital services while maintaining continuous care team involvement across the patient journey—spanning consultations, hospitalization, and post-discharge recovery. This approach positions Even as a vertically integrated healthcare provider rather than a point-solution platform.
The Series B round marks Even's second major funding event in 2026, following a $20 million Series A led by Lachy Groom and Alpha Wave in January. This accelerated capital raise sequence underscores sustained investor appetite for the company's scaling trajectory. Even's financial performance reflects both rapid expansion and the typical investment profile of early-stage health tech: FY25 revenues reached INR 25.43 crore, representing more than 4x year-over-year growth, while operating losses expanded to INR 90.15 crore. The company has not yet filed FY26 financials, making this funding round a critical juncture as Even progresses from Series B capital deployment into operational maturity and profitability pathways.
Khosla Ventures' role as lead investor is significant, as the firm has established a track record in backing healthcare infrastructure plays across emerging markets. The participation of multiple institutional investors—alongside continued backing from existing Series A investors—suggests alignment on Even's unit economics and market expansion strategy within India's fragmented healthcare delivery landscape.
Founded in 2020, Even Healthcare differentiates itself through a membership-based care model that departs from traditional transactional healthcare engagement. The company provides integrated primary care, diagnostics, and hospital services while maintaining continuous care team involvement across the patient journey—spanning consultations, hospitalization, and post-discharge recovery. This approach positions Even as a vertically integrated healthcare provider rather than a point-solution platform.
The Series B round marks Even's second major funding event in 2026, following a $20 million Series A led by Lachy Groom and Alpha Wave in January. This accelerated capital raise sequence underscores sustained investor appetite for the company's scaling trajectory. Even's financial performance reflects both rapid expansion and the typical investment profile of early-stage health tech: FY25 revenues reached INR 25.43 crore, representing more than 4x year-over-year growth, while operating losses expanded to INR 90.15 crore. The company has not yet filed FY26 financials, making this funding round a critical juncture as Even progresses from Series B capital deployment into operational maturity and profitability pathways.
Khosla Ventures' role as lead investor is significant, as the firm has established a track record in backing healthcare infrastructure plays across emerging markets. The participation of multiple institutional investors—alongside continued backing from existing Series A investors—suggests alignment on Even's unit economics and market expansion strategy within India's fragmented healthcare delivery landscape.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.